Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing...